# A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

> **NCT00053638** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 345 (—)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** efavirenz
- **DRUG:** tenofovir
- **DRUG:** abacavir/lamivudine

## Key facts

- **NCT ID:** NCT00053638
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 345 (—)
- **Last updated:** 2010-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053638, "A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00053638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*